Outset Medical (NASDAQ:OM) Issues Earnings Results

Outset Medical (NASDAQ:OM) announced its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04), Zacks reports. Outset Medical had a negative net margin of 122.84% and a negative return on equity of 164.92%. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Trading Up 3.5 %

Shares of NASDAQ:OM opened at $0.94 on Thursday. The business’s 50 day simple moving average is $0.96 and its 200-day simple moving average is $0.85. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04. Outset Medical has a 12 month low of $0.44 and a 12 month high of $5.22.

Insider Transactions at Outset Medical

In related news, CEO Leslie Trigg sold 33,227 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $0.81, for a total value of $26,913.87. Following the sale, the chief executive officer now owns 861,397 shares of the company’s stock, valued at approximately $697,731.57. This represents a 3.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel John L. Brottem sold 32,930 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total value of $26,344.00. Following the completion of the sale, the general counsel now directly owns 181,188 shares in the company, valued at approximately $144,950.40. The trade was a 15.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 292,750 shares of company stock valued at $244,707 in the last quarter. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price target on shares of Outset Medical in a research note on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.